Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06345183
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-03
First Post:
2024-03-28
Brief Title:
Real-World Outcomes of NivolumabIpilimumab and PembrolizumabLenvatinib Among US Advanced Renal Cell Carcinoma aRCC Patients
Sponsor:
Organization:
Bristol-Myers Squibb